Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)

BIOLOGICAL2 trials

Sponsors

Bayer

Conditions

Macular DegenerationRetinal Vein Occlusion

Phase 3

Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)

CompletedNCT00637377

BayerMacular Degeneration

Start: 2008-04-30End: 2011-08-31Updated: 2014-12-12

Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)

CompletedNCT01012973

BayerRetinal Vein Occlusion

Start: 2009-10-31End: 2012-02-29Updated: 2014-11-03

Related Papers

Seven-year outcomes following intensive anti-vascular endothelial growth factor therapy in patients with exudative age-related macular degeneration.

2023-03-174 citations

Changes in neovascular activity following fixed dosing with an anti-vascular endothelial growth factor agent over 52 weeks in the phase III VIEW 1 and VIEW 2 studies

British Journal of Ophthalmology2019-12-115 citations

Improvement in vision-related function with intravitreal aflibercept: data from phase 3 studies in wet age-related macular degeneration.

2014-11-0639 citations

Efficacy and safety of intravitreal aflibercept injection in wet age-related macular degeneration: outcomes in the Japanese subgroup of the VIEW 2 study

British Journal of Ophthalmology2014-08-0848 citations